Orforglipron vs Tirzepatide: Comparing a Future Pill with Today's Licensed Treatment

The biggest misconception: that orforglipron is about to replace Mounjaro

Search results for orforglipron vs tirzepatide carry an implicit assumption: that orforglipron is either already available or days away. Neither is true in the UK. Orforglipron is an investigational small-molecule GLP-1 receptor agonist developed by Eli Lilly — the same company behind tirzepatide. Unlike peptide-based GLP-1 medicines, it does not require refrigeration and can be taken as a standard oral tablet without the strict 30-minute empty-stomach window that the Wegovy pill requires. Those are real practical advantages. But phase 3 trial data, while encouraging, have not yet been reviewed by the MHRA, and no submission for UK authorisation had been granted at the time of writing. A medicine's trial results and its shelf availability are separated by a regulatory process that typically takes years. Tirzepatide, by contrast, received its UK weight-management licence and a NICE recommendation (TA1026) in December 2024. It is here, it is licensed, and it can be prescribed today for eligible adults.

What the trial data actually shows, and what it cannot tell us yet

Comparing the two medicines on efficacy requires some care, because the trials are not directly head-to-head. In SURMOUNT-1, published in the New England Journal of Medicine, tirzepatide at 15mg produced an average body-weight reduction of around 20–21% over 72 weeks in adults without diabetes. Orforglipron's phase 3 ATTAIN-1 data, presented in 2025, reported average weight loss of roughly 7–8% at 36 mg over 40 weeks in a trial with a shorter duration and different design, making direct percentage comparisons misleading without adjustment for time and population. The mechanism gap matters too: tirzepatide activates both GIP and GLP-1 receptors, a dual action that appears to drive larger average losses than single-pathway GLP-1 medicines in head-to-head evidence, and our page on how a standard GLP-1 approach compares with tirzepatide's dual-receptor mechanism sets out that distinction clearly. For anyone curious about how tirzepatide compares with another pipeline candidate, our page on how retatrutide, a triple-agonist still in trials, stacks up against tirzepatide covers that question in detail. Orforglipron's oral convenience may eventually close some of that efficacy gap in real-world populations where injection hesitancy limits adherence, but that remains speculative until UK-specific regulatory data land.

Sources: NICE TA1026 (tirzepatide); NEJM SURMOUNT-1; Eli Lilly ATTAIN-1 presentation data, 2025 (orforglipron figures not yet peer-reviewed in final form at time of writing).

Orforglipron vs Mounjaro: the practical reality for UK patients right now

The orforglipron vs Mounjaro framing is essentially a question about present versus future. Mounjaro is stocked, prescribed and dispatched by regulated UK pharmacies today. Orforglipron has no UK marketing authorisation, which means no UK prescriber can legally issue a prescription for it for weight management. Anyone offering it online is operating outside the licensed supply chain, a serious safety concern given the scale of counterfeit activity the MHRA has documented. If the arrival of a convenient daily pill appeals, it is worth noting that UK-licensed oral options already exist: the Wegovy tablet received MHRA approval in June 2026, and patients who want to understand how tirzepatide and Mounjaro relate to each other before choosing will find that question answered in full. For patients weighing up the injection versus a pill specifically, that is already a live clinical conversation, and those who want a broader view of where retatrutide sits relative to tirzepatide across the main efficacy and safety measures will find a detailed breakdown on that page. And if you are deciding between tirzepatide and other pipeline molecules, the pemvidutide comparison covers another candidate still in development. The short answer: orforglipron may reach UK patients in future years; Mounjaro reaches them on the next working day. Which is right for you is not a marketing decision, it is a clinical one, made with a prescriber who knows your full picture. Those researching the difference between tirzepatide and Manjaro as brand names will find that distinction worth clarifying before any consultation. The clinical team at nume reviews every consultation personally before any treatment is approved or dispatched.